The role of HIV asymptomatic status when starting ART on adherence and treatment outcomes and implications for test and treat: the Swiss HIV Cohort Study.

Glass, Tracy R; Günthard, Huldrych; Calmy, Alexandra; Bernasconi, Enos; Scherrer, Alexandra U; Battegay, Manuel; Steffen, Ana; Böni, Jürg; Yerly, Sabine; Klimkait, Thomas; Cavassini, Matthias; Furrer, Hansjakob (2020). The role of HIV asymptomatic status when starting ART on adherence and treatment outcomes and implications for test and treat: the Swiss HIV Cohort Study. (In Press). Clinical infectious diseases Oxford University Press 10.1093/cid/ciaa239

[img] Text
Glass_Asymptomatic_HIV_and_clinical_outcomes_2020_CID.pdf - Accepted Version
Restricted to registered users only until 12 March 2021.
Available under License Publisher holds Copyright.

Download (286kB) | Request a copy

BACKGROUND Since the advent of universal test and treat policies, a higher share of people living with HIV (PLHIV) initiating ART are asymptomatic with a preserved immune system. We explored the potential impact of asymptomatic status on adherence and clinical outcomes. METHODS PLHIV registered in the Swiss HIV Cohort Study (SHCS) between 2003 and 2018. Asymptomatic: CDC-stage A within 30 days of starting ART. Non-adherence: any self-reported missed doses. Viral failure: viral load>50 copies/mL on two consecutive measurements after >24 weeks on ART. Using logistic regression models, we measured the variables associated with asymptomatic status and adherence and Cox proportional hazard models to assess the association between symptom status and viral failure. RESULTS Of 7131 PLHIV, 76% started ART when asymptomatic. In multivariable logistic regression models, asymptomatic PLHIV were more likely to be younger, men having sex with men, more educated, having unprotected sex, have a stable HIV-positive partner, lower viral load, and have started ART in later calendar years. Asymptomatic status was not associated with reported non-adherence during follow-up (OR 1.03, 95% CI: 0.93-1.15) while 1478 PLHIV (22%) experienced viral failure a median of 1.9 years (IQR: 1.1-4.2) after starting ART. Asymptomatic PLHIV were at a decreased risk of viral failure (adjusted hazard ratio 0.87, 95% CI: 0.76-1.00, p=0.05) and less likely to develop resistance (14% versus 27%, p<0.001) than symptomatic PLHIV. CONCLUSIONS Despite concerns regarding lack of readiness, our study found no evidence of adherence issues or worse clinical outcomes in asymptomatic compared to symptomatic PLHIV starting ART.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology

UniBE Contributor:

Furrer, Hansjakob

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1537-6591

Publisher:

Oxford University Press

Language:

English

Submitter:

Annelies Luginbühl

Date Deposited:

16 Jun 2020 08:38

Last Modified:

16 Jun 2020 08:38

Publisher DOI:

10.1093/cid/ciaa239

PubMed ID:

32157270

Uncontrolled Keywords:

HIV antiretroviral therapy asymptomatic clinical outcomes universal test and treat

BORIS DOI:

10.7892/boris.144046

URI:

https://boris.unibe.ch/id/eprint/144046

Actions (login required)

Edit item Edit item
Provide Feedback